Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Activating Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03940703
What this trial is testing

Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Who this might be right for
Non-small Cell Lung Cancer
EMD Serono Research & Development Institute, Inc. 140
Post-approval studies (Phase 4)Ended earlyNCT02299765
What this trial is testing

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
Sichuan University 61
Not applicableTemporarily Not AvailableNCT01297101
What this trial is testing

Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Chest Hospital
Large-scale testing (Phase 3)Ended earlyNCT02588261
What this trial is testing

ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Astellas Pharma Global Development, Inc. 530
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167
What this trial is testing

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 19
Large-scale testing (Phase 3)UnknownNCT02929693
What this trial is testing

Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

Who this might be right for
Cancer
Shanghai University of Traditional Chinese Medicine 198
Testing effectiveness (Phase 2)UnknownNCT01955421
What this trial is testing

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Who this might be right for
Advanced Stage Non Small Cell Lung Cancer
Sun Yat-sen University 224
Testing effectiveness (Phase 2)Study completedNCT05146219
What this trial is testing

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Who this might be right for
NSCLCEGFR Activating MutationBrain Metastases+1 more
TYK Medicines, Inc 29
Not applicableUnknownNCT03916913
What this trial is testing

TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Metastatic
Chinese Academy of Medical Sciences 85
Testing effectiveness (Phase 2)Active Not RecruitingNCT04545710
What this trial is testing

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

Who this might be right for
Lung Cancer
University of California, San Diego 18
Testing effectiveness (Phase 2)UnknownNCT04636593
What this trial is testing

Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerStage III NSCLCEGFR Activating Mutation
First People's Hospital of Hangzhou 43
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05778149
What this trial is testing

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Who this might be right for
AumolertinibAnlotinibTP53+2 more
Tianjin Medical University Cancer Institute and Hospital 47
Testing effectiveness (Phase 2)UnknownNCT04470076
What this trial is testing

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation

Who this might be right for
Non Small Cell Lung CancerSurgeryEGFR Activating Mutation+2 more
Fifth Affiliated Hospital, Sun Yat-Sen University 30
Early research (Phase 1)Study completedNCT03516214
What this trial is testing

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Who this might be right for
Bronchial Neoplasms
University of Cologne 18
Not applicableStudy completedNCT03944265
What this trial is testing

Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

Who this might be right for
Activating ALK Gene Mutation NegativeActivating EGFR Gene Mutation NegativeActivating ROS1 Gene Mutation Negative+5 more
Thomas Jefferson University 14
Not applicableEnrolling By InvitationNCT06730477
What this trial is testing

Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma

Who this might be right for
Lung AdenocarcinomaEGFR Activating Mutation
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 500
Testing effectiveness (Phase 2)Study completedNCT01260181
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 30
Large-scale testing (Phase 3)Study completedNCT01887886
What this trial is testing

Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 10
Testing effectiveness (Phase 2)Ended earlyNCT02500927
What this trial is testing

ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Who this might be right for
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Astellas Pharma Inc 31
Not applicableEnded earlyNCT02483416
What this trial is testing

Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 30
Next Page